• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » FDA updates warning on SynCardia drivers

FDA updates warning on SynCardia drivers

October 26, 2016 By Fink Densford

SynCardiaSynCardia Systems today released an update on issues with its Temporary Total Artificial Heart’s Companion 2 driver system and released information on neurological adverse event issues with its pneumatic Freedom driver system.

A post-approval study in June 2015 indicated a higher mortality rate for a subgroup of patients using SynCardia’s TAH-t C2 driver system compared with its previous generation driver, the Circulatory Support System Console.

Updated results from a comparison of mortality rates between patients with the CSS Console and C2 Driver System indicated a continued higher mortality rate for patients requiring pre-implant circulatory rescue interventions. Mortality rates between the 2 driver systems were similar for patients outside the subgroup.

For patients who received pre-implant circulatory interventions, those on the C2 driver had a 39% mortality rate, 14% higher than those on the CSS Console. Patients on the C2 driver outside the subgroup exhibited a 27% mortality rate, only 6% higher than those on the CSS console.

The company also reported that patients treated with the C2 driver exhibited a 15% higher rate of neurological adverse events, at 31% compared to 16% for patients on the CSS Console.

SynCardia warned that the results were not adjusted for potential confounds, and were not stratified by pre-implant circulatory rescue intervention status.

“The Neurological AE rate will continue to be monitored, and additional analyses will be performed as appropriate in the future,” SynCardia wrote in its update. The company said it did not know the root cause for the observed differences, and that its “existing data is limited.”

The company also released data on a 3rd driver, the Freedom pneumatic driver system, which is also available for use with the TAH-t. The Freedom Driver is portable and usable outside of the hospital.

SynCardia said it is ‘aware of recent reports of serious, life-threatening TAH-t device malfunctions” involving the Freedom Driver system, including sudden cessation of TAH-t pumping without warning alarms or signs of an impending malfunction.

The Freedom Driver system was the subject of a Class 1 recall initiated last year, SynCardia said, and added that it is working with the FDA to assess malfunction reports.

The FDA issued its own instructions, advising instructors to carefully consider the mortality and neurological adverse events reports when making treatment decisions and device selections. The agency also advised patients and practitioners to report any adverse events or suspected adverse events with the devices, and to return any that they suspect are associated with such events.

In September, SynCardia released info on the Class 1 recall of its total artificial heart devices, citing a single incident in which a patient lost consciousness but suffered no permanent injury. All devices affected by the recall were taken off the market within 8 days after the company’s initial warning on August 6.

Earlier in September, the FDA slapped the action with Class I status, denoting an issue that could result in serious injury or death. The problem involved the SynCardia device’s Freedom driver, which is attached to the heart pump and operates and monitors the device. A specific part of the Freedom Driver mechanism may fail and cause the device to stop pumping; patients with driver failures do not receive any advanced warning of the failure, only a red light and loud continuous alarm that sound after the failure.

In the same month, SynCardia said that it was acquired by affiliates of investment firm Versa Capital Management, with current president & CEO Michael Garippa set to keep the corner office.

Tuscon-based SynCardia makes an artificial heart system designed to replace the functions of both the left and right ventricles and all 4 heart valves.

On August 16, SynCardia announced it would emerge from Chapter 11 reorganization with a new owner, Sindex, while rebuking claims from a french competitor Carmat (FRA:CXT) that it was exiting the market.

Filed Under: Cardiac Implants, Cardiovascular, Food & Drug Administration (FDA), Recalls Tagged With: SynCardia

In case you missed it

  • Learn What Quality Trends to Watch for in 2021
  • HHS could make permanent pandemic-related exemptions for some devices
  • Medtechs can’t set digital strategies aside – DTW Podcast
  • NIH increases PhysIQ contract to $6.6M
  • Senseonics announces $50M from stock offering
  • Protolabs to acquire 3D Hubs for up to $330M
  • TransEnterix receives CE Mark for AI for its robotic surgery system
  • Hillrom to buy Bardy Diagnostics for $375M
  • Philips aquires Capsule Technologies and its medical device data tech
  • Masimo launches iSirona connectivity hub
  • Thermo Fisher to acquire Mesa Biotech
  • MedTech 100 roundup: Finally a dip as industry stays relatively strong
  • These medtech stocks performed the best in 2020
  • Medtronic launches deep brain stim trial for Parkinson’s disease
  • Former FDA commissioner Kessler to help lead Biden’s COVID-19 response
  • Facial swelling and COVID-19 vaccines: 4 facts
  • Here’s what molecular shape can tell you about pharma innovation

RSS From Medical Design & Outsourcing

  • These medtech stocks performed the best in 2020
    While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward. Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while… […]
  • Covestro tests plastics against high-strength hospital disinfectants
    Covestro announced that it recently teamed with disinfectant manufacturer Metrex to test six different Covestro polycarbonate materials against three of Metrex’s products, which are widely used throughout the healthcare industry. As is customary for rapidly assessing the compatibility of plastics to disinfectants, test specimens were pre-strained and underwent several wipe-and-dry cycles with Metrex disinfectants to… […]
  • Integer expands N.Y. battery plant
    Integer announced today that it recently broke ground on an expansion of its Alden, N.Y., facility to accommodate new equipment that will substantially increase the plant’s production capacity for rechargeable Xcellion lithium-ion batteries. The project kicked off in mid-December 2020 and will add both production equipment and a build-out of Integer’s existing facility. The company… […]
  • Diversified Plastics adds high-efficiency vertical presses
    Diversified Plastics (DPI) announced that it recently installed six all-electric vertical injection molding presses. These presses will join DPI’s existing assemblage of vertical presses and provide increased production capacity to meet growing demand from medical device and other original equipment manufacturers (OEMs). DPI uses vertical presses for over-molding and insert-molding, capabilities often required for medical… […]
  • Traco Power expands power supply line for portable medical equipment
    Traco Power announced that it has expanded its TPP 450 high-density 3×5 power supply series. The series now offers Protection Class II models (TPP 450BA-M Open-Frame Models and TPP 450B-M Enclosed with Fan Models), designed for non-stationary requirements where connection to ground is not possible. Key approvals on the original series remain on the expanded… […]
  • Reflow Medical launches low-profile reinforced support catheters
    Reflow Medical today announced it has launched its Reflow Spex Low Profile reinforced support catheters. The Spex LP catheters are designed to provide the lowest profile tip to access and cross the tightest and most complex lesions with a supportive system. They come in 0.014 in. and 0.018 in. sizes and can be combined with… […]
  • Former CDER head Woodcock to lead FDA for now
    FDA veteran Dr. Janet Woodcock has been tapped as interim FDA commissioner by the Biden administration, according to published reports. An article by BioCentury also said that former FDA commissioner David Kessler, who had been mentioned as a possible replacement for current commissioner Stephen Hahn, will be a consultant to the agency but will not… […]
  • What’s next for the FDA and for Stephen Hahn?
    Outgoing FDA commissioner Stephen Hahn says he needs some time to reflect on his future after leading the FDA for a little over a year. It’s hard to blame him. Hahn’s brief tenure at FDA has been rocky, to say the least. (News of his temporary replacement broke on Thursday, when the incoming Biden administration… […]
  • Medicare to cover breakthrough devices
    FDA-designated breakthrough devices will have Medicare coverage the same day they are approved, under a final rule issued this week by the Centers for Medicare and Medicaid Services (CMS). The Medicare Coverage of Innovative Technology (MCIT) rule will provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices… […]
  • FDA debuts plan for AI-based Software as a Medical Device
    The FDA today released its first plan to regulate artificial intelligence/machine learning (AI/ML)-based Software as a Medical Device (SaMD). The plan is a response to feedback received from the agency’s April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device.” It outlines five actions that the FDA… […]
  • EU allows remote audits for medical devices during pandemic
    The European Union has announced that it will temporarily allow remote audits of medical devices and in vitro diagnostics under the new regulations (MDR IVDR), set to go into effect on May 2021 and 2022 respectively. In a document published Monday, the European Commission agreed with industry and notified bodies that the ongoing COVID-19 pandemic… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS